TP53 and acute myeloid leukemia: In addition, the ongoing Beat AML phase 1b/2 study of TP-0903 and decitabine targeting mutant TP53 and/or complex karyotype in patients with untreated AML (NCT03013998) reported a composite CR (CRh/Cri) rate of 66% achieving minimal residual disease negativity at dose level 1, leading to selection of this dose as the recommended phase 2 dose [118].